COVID-19 & CancerFreeGuest Editorial CCC19 data point to extensive use of hydroxychloroquine, azithromycin, or both, by patients with cancer and COVID-19 May 29, 2020Vol.46 No.22By Otis W. Brawley
Conversation with The Cancer LetterCOVID-19 & CancerFree Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge May 29, 2020Vol.46 No.22By Paul Goldberg
Drugs & TargetsFree Opdivo + Yervoy combination receives FDA approval for first-line mNSCLC (PD-L1 tumor expression ≥1%) May 22, 2020Vol.46 No.21
Drugs & TargetsFree Pomalidomide receives accelerated approval to for Kaposi sarcoma May 22, 2020Vol.46 No.21
Drugs & TargetsFree Rucaparib receives FDA approval for BRCA-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree Ripretinib receives FDA approval for advanced gastrointestinal stromal tumor May 22, 2020Vol.46 No.21
Drugs & TargetsFree Tecentriq receives FDA approval as first-line monotherapy in NSCLC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Olaparib receives FDA approval for HRR gene-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree BRACAnalysis CDx receives approval as companion diagnostic for Lynparza in mCRPC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Karyopharm submits sNDA for Xpovio as treatment for multiple myeloma after at least one prior line of therapy May 22, 2020Vol.46 No.21
